A seguir

Reprodução automática

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

0 Visualizações • 07/14/23
Compartilhar
Embutir
administrator
administrator
Assinantes
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Mostre mais
0 Comentários sort Ordenar por
Comentários do Facebook

A seguir

Reprodução automática